Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
| Autor: | Nahid Beladi Moghadam, Katayoun Alikhani, Jamshid Lotfi, Saeideh Khorramnia, Sirous Jafarian, Samira Yadegari, Mohammad Reza Gheini, Sanaz Ahmadi Karvigh, Behrouz Nikbin, Mohammad Reza Motamed, Mansoureh Togha, Mohammad Ali Sahraian, Mohammad Hossien Harirchian, Aida Aghsaie, Mandana Mohyeddin Bonab, Seyed Massoud Hosseinian |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Fever Nausea Drug Resistance Medicine (miscellaneous) Gadolinium Mesenchymal Stem Cell Transplantation Autoantigens Transplantation Autologous Disease-Free Survival Humans Medicine Adverse effect Expanded Disability Status Scale business.industry Multiple sclerosis Mesenchymal stem cell General Medicine Multiple Sclerosis Chronic Progressive medicine.disease Magnetic Resonance Imaging Surgery Transplantation Treatment Outcome Postoperative Nausea and Vomiting Disease Progression Vomiting Female medicine.symptom business Postoperative nausea and vomiting Follow-Up Studies |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 1574-888X |
| Popis: | Despite updating knowledge and a growing number of medications for multiple sclerosis (MS), no definite treatment is available yet for patients suffering from progressive forms of the disease. Autologous bone marrow derived mesenchymal stem cell (BM-MSC) transplantation is a promising method proposed as a therapy for MS. Although the safety of these cells has been confirmed in hematological, cardiac and inflammatory diseases, its efficacy in MS treatment is still under study. Patients with progressive MS (expanded disability status scale score: 4.0 –6.50) unresponsive to conventional treatments were recruited for this study. Twenty-five patients [f/m: 19/6, mean age: 34.7±7] received a single intrathecal injection of ex-vivo expanded MSCs (mean dose: 29.5×106 cells). We observed their therapeutic response for 12 months. Associated short-term adverse events of injection consisted of transient low-grade fever, nausea /vomiting, weakness in the lower limbs and headache. No major delayed adverse effect was reported. 3 patients left the study for personal reasons. The mean (SD) expanded disability status scale (EDSS) score of 22 patients changed from 6.1 (0.6) to 6.3 (0.4). Clinical course of the disease (measured by EDSS) improved in 4, deteriorated in 6 and had no change in 12 patients. In MRI evaluation, 15 patients showed no change, whereas 6 patients showed new T2 or gadolinium enhanced lesions (1 lost to follow-up). It seems that MSC therapy can improve/stabilize the course of the disease in progressive MS in the first year after injection with no serious adverse effects. Repeating the study with a larger sample size, booster injections and longer follow-up using a controlled study design is advised. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|